HealthQuill Pharma
Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an early-stage experimental therapy and to develop once-in-a-lifetime treatments for cardiovascular diseases.
Drugs Health Pharma

Eli Lilly to buy Verve for $1.3 billion, expands heart therapy segment

HQ Team June 19, 2025: Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an.

Read More
The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’ living cells to China and other “hostile countries” for the fear of genetic data misuse.
Drugs Health Pharma

US to review trials to stop genetic data misuse by China, ‘hostile’ nations

HQ Team June 19, 2025: The US drug regulator has announced an immediate review of new clinical trials that involve sending American citizens’.

Read More
The US drug regulator approved Moderna Inc.’s respiratory syncytial virus vaccine for expanded use among people aged between 18 and 59 years.
Drugs Health Pharma

US regulator gives nod for Moderna’s expanded use of mRNA vaccine

HQ Team June 13, 2025: The US drug regulator approved Moderna Inc.’s respiratory syncytial virus vaccine for expanded use among people aged between.

Read More
Rein Therapeutics, Inc. has paused its enrollment and patient dosing at its US clinical trial sites testing a lung disease drug, after the regulator placed the experiment on clinical hold. 
Drugs Health Pharma

Rein Therapeutics’ trial drug for lung disease disorder put on clinical hold

HQ Team July 13, 2025: Rein Therapeutics, Inc., has paused its enrollment and patient dosing at its US clinical trial sites testing a.

Read More
UroGen Pharma Ltd.’s therapy to treat adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer has been approved by the US Food and Drug Administration.
Drugs Health Pharma

FDA approves UroGen’s muscle-invasive bladder cancer therapy

HQ Team June 13, 2025: UroGen Pharma Ltd.’s therapy to treat adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer has been.

Read More
Denmark’s Novo Nordisk will advance its experimental drug amycretin, in both injection and oral forms, into end-stage trials in weight management based on completed clinical studies, according to a company statement.
Drugs Health Pharma

Novo Nordisk’s obesity drug to begin end-stage trials in early 2026

HQ Team July 13, 2025: Denmark’s Novo Nordisk A/S will advance its experimental drug amycretin, in both injection and oral forms, into end-stage.

Read More
Germany’s BioNTech SE will acquire CureVac N.V., which develops therapies based on messenger RNA, for $1.25 billion in an all-stock deal to expand the former’s mRNA-based cancer immunotherapy candidates.
Drugs Health Pharma

BioNTech SE to acquire CureVac for $1.25 billion in all-stock deal

HQ Team June 12, 2025: Germany’s BioNTech SE will acquire CureVac N.V., which develops therapies based on messenger RNA, for $1.25 billion in.

Read More
A machine developed by US-based HistoSonics Inc. to treat patients with primary and secondary liver tumours and other hard-to-reach tumours will be installed at the UK’s Cambridge University Hospitals later this year.
Drugs Health Pharma

UK patients to be first to get non-invasive liver cancer treatment in Europe

HQ Team June 12, 2025: A machine developed by US-based HistoSonics Inc. to treat patients with primary and secondary liver tumours and other.

Read More
Novavax Inc.’s investigational vaccine that protects against both Covid-19 and seasonal flu in a single shot has generated a “strong immune response” during end-stage trials, the company stated.
Drugs Health Pharma

Novavax’s Covid-19-influenza vaccine trial yields ‘strong’ immune response

HQ Team June 12, 2025: Novavax Inc.’s investigational vaccine that protects against both Covid-19 and seasonal flu in a single shot has generated.

Read More
The US Food and Drug Administration has approved Nuvation Bio Inc.’s medicine for adults who have a rare type of lung cancer caused by a specific genetic change.
Drugs Health Pharma

US drug regulator greenlights Nuvation’s rare lung cancer medicine

HQ Team June 11, 2025: The US Food and Drug Administration has approved Nuvation Bio Inc.’s medicine for adults who have a rare.

Read More